| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 20 | 2021 | 288 | 6.450 |
Why?
|
| Catheter Ablation | 12 | 2020 | 233 | 2.020 |
Why?
|
| Myocytes, Cardiac | 6 | 2020 | 275 | 1.850 |
Why?
|
| Atrial Flutter | 6 | 2020 | 33 | 1.410 |
Why?
|
| Heart-Assist Devices | 5 | 2020 | 731 | 1.280 |
Why?
|
| Heart Rate | 6 | 2021 | 492 | 1.130 |
Why?
|
| Heart Failure | 6 | 2022 | 1204 | 1.100 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2020 | 58 | 1.050 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 5 | 2018 | 20 | 1.040 |
Why?
|
| Defibrillators, Implantable | 5 | 2022 | 129 | 1.030 |
Why?
|
| Cardiac Pacing, Artificial | 4 | 2018 | 87 | 1.020 |
Why?
|
| Oxidative Stress | 4 | 2019 | 447 | 0.990 |
Why?
|
| Tachycardia, Ventricular | 4 | 2020 | 115 | 0.950 |
Why?
|
| Electrocardiography | 7 | 2021 | 478 | 0.880 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 64 | 0.860 |
Why?
|
| Pacemaker, Artificial | 5 | 2021 | 87 | 0.790 |
Why?
|
| Energy Metabolism | 2 | 2019 | 271 | 0.790 |
Why?
|
| Atrioventricular Block | 2 | 2018 | 23 | 0.770 |
Why?
|
| Enzyme Activators | 1 | 2020 | 14 | 0.770 |
Why?
|
| Mitochondria | 3 | 2019 | 535 | 0.710 |
Why?
|
| Aspirin | 1 | 2020 | 156 | 0.690 |
Why?
|
| Heart Ventricles | 4 | 2020 | 760 | 0.690 |
Why?
|
| Atrioventricular Node | 4 | 2017 | 33 | 0.680 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 9 | 0.680 |
Why?
|
| Metformin | 1 | 2020 | 128 | 0.670 |
Why?
|
| Heart Atria | 2 | 2020 | 250 | 0.660 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2022 | 187 | 0.660 |
Why?
|
| Cardiomyopathies | 4 | 2023 | 240 | 0.590 |
Why?
|
| Atrial Septum | 1 | 2016 | 9 | 0.580 |
Why?
|
| Torsades de Pointes | 1 | 2016 | 7 | 0.570 |
Why?
|
| Fibroma | 1 | 2016 | 33 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 350 | 0.560 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 34 | 0.560 |
Why?
|
| Heart Neoplasms | 1 | 2016 | 62 | 0.550 |
Why?
|
| Mitochondria, Heart | 4 | 2020 | 50 | 0.550 |
Why?
|
| Benzodiazepines | 1 | 2016 | 65 | 0.550 |
Why?
|
| Myocardial Stunning | 1 | 2015 | 12 | 0.530 |
Why?
|
| Cocaine | 1 | 2016 | 76 | 0.530 |
Why?
|
| Incidence | 6 | 2018 | 1577 | 0.500 |
Why?
|
| Bundle of His | 3 | 2019 | 42 | 0.490 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2013 | 57 | 0.490 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2013 | 11 | 0.470 |
Why?
|
| Male | 27 | 2022 | 40965 | 0.470 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 462 | 0.460 |
Why?
|
| Middle Aged | 20 | 2022 | 25028 | 0.460 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2013 | 12 | 0.460 |
Why?
|
| Equipment Failure | 2 | 2018 | 119 | 0.440 |
Why?
|
| Humans | 35 | 2023 | 86643 | 0.430 |
Why?
|
| Diazoxide | 3 | 2007 | 19 | 0.430 |
Why?
|
| Electric Power Supplies | 1 | 2011 | 9 | 0.420 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 394 | 0.420 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 123 | 0.420 |
Why?
|
| Female | 25 | 2022 | 44532 | 0.420 |
Why?
|
| Aged | 19 | 2022 | 18415 | 0.400 |
Why?
|
| Heart Conduction System | 3 | 2020 | 108 | 0.400 |
Why?
|
| Ion Channels | 1 | 2013 | 246 | 0.400 |
Why?
|
| Bundle-Branch Block | 3 | 2022 | 48 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 3092 | 0.380 |
Why?
|
| Prevalence | 3 | 2019 | 1239 | 0.370 |
Why?
|
| Heart Septum | 2 | 2020 | 45 | 0.370 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1924 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2015 | 318 | 0.350 |
Why?
|
| Device Removal | 2 | 2021 | 161 | 0.350 |
Why?
|
| Aged, 80 and over | 7 | 2022 | 6509 | 0.340 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2207 | 0.340 |
Why?
|
| Myocardium | 3 | 2020 | 529 | 0.340 |
Why?
|
| Atrial Remodeling | 2 | 2020 | 17 | 0.340 |
Why?
|
| Ultrasonography, Interventional | 2 | 2020 | 121 | 0.320 |
Why?
|
| KATP Channels | 1 | 2007 | 19 | 0.310 |
Why?
|
| Fibrosis | 2 | 2020 | 203 | 0.300 |
Why?
|
| Adenosine Triphosphate | 5 | 2013 | 314 | 0.290 |
Why?
|
| Risk Factors | 7 | 2020 | 5417 | 0.280 |
Why?
|
| Animals | 12 | 2023 | 26582 | 0.270 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3640 | 0.260 |
Why?
|
| Reactive Oxygen Species | 4 | 2015 | 480 | 0.250 |
Why?
|
| Sex Factors | 3 | 2018 | 1054 | 0.250 |
Why?
|
| Stroke Volume | 3 | 2020 | 456 | 0.250 |
Why?
|
| Succinate Dehydrogenase | 3 | 2019 | 17 | 0.250 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2022 | 68 | 0.240 |
Why?
|
| Mice | 6 | 2023 | 11352 | 0.230 |
Why?
|
| Potassium Channels | 2 | 2003 | 340 | 0.230 |
Why?
|
| Death, Sudden | 1 | 2002 | 40 | 0.210 |
Why?
|
| Tachycardia | 2 | 2019 | 35 | 0.210 |
Why?
|
| Retrospective Studies | 8 | 2020 | 8489 | 0.210 |
Why?
|
| Stress, Physiological | 1 | 2003 | 227 | 0.200 |
Why?
|
| Adult | 7 | 2023 | 25648 | 0.200 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1673 | 0.200 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 58 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 3 | 2007 | 49 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 219 | 0.190 |
Why?
|
| Gadolinium | 1 | 2020 | 103 | 0.190 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 59 | 0.180 |
Why?
|
| Cicatrix | 1 | 2020 | 63 | 0.180 |
Why?
|
| Primary Prevention | 1 | 2020 | 85 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7993 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2020 | 4213 | 0.180 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 47 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1540 | 0.180 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 159 | 0.180 |
Why?
|
| Potassium | 2 | 2016 | 281 | 0.180 |
Why?
|
| Purkinje Fibers | 1 | 2019 | 27 | 0.170 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 25 | 0.170 |
Why?
|
| Enzyme Activation | 1 | 2020 | 692 | 0.170 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 73 | 0.170 |
Why?
|
| Atrial Appendage | 1 | 2018 | 26 | 0.160 |
Why?
|
| Body Surface Potential Mapping | 1 | 2017 | 22 | 0.160 |
Why?
|
| Isoproterenol | 2 | 2016 | 59 | 0.160 |
Why?
|
| Thromboembolism | 1 | 2018 | 119 | 0.160 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.150 |
Why?
|
| Creatine Kinase | 3 | 2007 | 52 | 0.150 |
Why?
|
| Venae Cavae | 1 | 2017 | 14 | 0.150 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 23 | 0.150 |
Why?
|
| Age Factors | 3 | 2018 | 1851 | 0.150 |
Why?
|
| Hydroxy Acids | 3 | 2007 | 9 | 0.150 |
Why?
|
| Decanoic Acids | 3 | 2007 | 11 | 0.150 |
Why?
|
| Renal Tubular Transport, Inborn Errors | 1 | 2016 | 3 | 0.140 |
Why?
|
| Sympathomimetics | 1 | 2016 | 12 | 0.140 |
Why?
|
| Nephrocalcinosis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Magnesium Sulfate | 1 | 2016 | 15 | 0.140 |
Why?
|
| Hypokalemia | 1 | 2016 | 29 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 50 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 66 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 827 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 213 | 0.140 |
Why?
|
| Ventricular Function, Left | 2 | 2015 | 592 | 0.140 |
Why?
|
| Chest Pain | 1 | 2016 | 42 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 746 | 0.140 |
Why?
|
| Cytochromes c | 2 | 2007 | 27 | 0.140 |
Why?
|
| Hypercalciuria | 1 | 2016 | 47 | 0.140 |
Why?
|
| Recurrence | 1 | 2018 | 1139 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 429 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 48 | 0.130 |
Why?
|
| Cell Hypoxia | 2 | 2007 | 164 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 204 | 0.130 |
Why?
|
| Connexin 43 | 1 | 2015 | 94 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 16 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 329 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 154 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 1863 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2232 | 0.120 |
Why?
|
| Connexins | 1 | 2015 | 200 | 0.120 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2013 | 5 | 0.120 |
Why?
|
| Uncoupling Protein 3 | 1 | 2013 | 9 | 0.120 |
Why?
|
| Uncoupling Protein 2 | 1 | 2013 | 11 | 0.120 |
Why?
|
| United States | 4 | 2022 | 6672 | 0.110 |
Why?
|
| Coronary Occlusion | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 28 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 849 | 0.110 |
Why?
|
| Comorbidity | 2 | 2014 | 943 | 0.110 |
Why?
|
| Echocardiography | 2 | 2017 | 911 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1585 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1204 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 989 | 0.100 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2016 | 516 | 0.100 |
Why?
|
| Phenotype | 2 | 2015 | 2378 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1801 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.090 |
Why?
|
| Genotype | 1 | 2015 | 1851 | 0.090 |
Why?
|
| Rats | 3 | 2007 | 3990 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 376 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 3679 | 0.090 |
Why?
|
| Apoptosis | 1 | 2015 | 1683 | 0.080 |
Why?
|
| Cell Respiration | 1 | 2007 | 18 | 0.080 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 68 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 134 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 158 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2020 | 39 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2010 | 395 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2010 | 376 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 859 | 0.070 |
Why?
|
| Cell Survival | 1 | 2007 | 969 | 0.060 |
Why?
|
| Cardiotonic Agents | 2 | 2003 | 87 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 2261 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2023 | 44 | 0.060 |
Why?
|
| Muscle Development | 1 | 2023 | 41 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2003 | 14 | 0.060 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2003 | 50 | 0.060 |
Why?
|
| Cell Line | 1 | 2007 | 2468 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2003 | 56 | 0.060 |
Why?
|
| Nucleotides | 1 | 2003 | 95 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2003 | 96 | 0.050 |
Why?
|
| Nicorandil | 1 | 2002 | 1 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2002 | 55 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 2767 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 82 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 59 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 64 | 0.050 |
Why?
|
| Calcium | 2 | 2003 | 1156 | 0.050 |
Why?
|
| DNA Damage | 1 | 2003 | 366 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 152 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 239 | 0.050 |
Why?
|
| Endocardium | 1 | 2020 | 76 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2023 | 428 | 0.050 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 29 | 0.050 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 9 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2020 | 278 | 0.040 |
Why?
|
| Hypoxia | 1 | 2023 | 641 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 685 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 244 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1686 | 0.040 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 674 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 462 | 0.040 |
Why?
|
| Action Potentials | 1 | 2020 | 573 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 114 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 379 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 162 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 125 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 1078 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 228 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1538 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 263 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 5210 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2705 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 294 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 966 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3362 | 0.020 |
Why?
|
| Dinitrophenols | 1 | 2003 | 7 | 0.010 |
Why?
|
| Uncoupling Agents | 1 | 2003 | 15 | 0.010 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2003 | 7 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 2003 | 27 | 0.010 |
Why?
|
| Succinates | 1 | 2003 | 21 | 0.010 |
Why?
|
| Electron Transport | 1 | 2003 | 71 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 60 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 73 | 0.010 |
Why?
|
| Ischemic Preconditioning | 1 | 2003 | 37 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 180 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1621 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2003 | 153 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 396 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2271 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2003 | 324 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 1513 | 0.010 |
Why?
|